Breakthrough in the manufacture of red blood cells.
BRISTOL, U.K., March 23, 2017 -- Researchers here have generated the first immortalized cell lines that allow more efficient manufacture of red blood cells.
The team from the University of Bristol and NHS Blood and Transplant manufactured red blood cells in a more efficient scale than was previously possible.
If clinical tests are successful, the results could lead to a safe source of transfusions for people with rare blood types, and in areas of the world where blood supplies are inadequate or unsafe.
Previously, research in this field focused on growing donated stem cells straight into mature red blood cells. However, that method presently produces small numbers of mature cells and requires repeat donations.
The team has now developed a robust and reproducible technique that allows the production of immortalized erythroid cell lines from adult stem cells. These premature red cells can be cultured indefinitely, allowing larger-scale production, before being differentiated into mature red blood cells.
Earlier approaches to producing red blood cells have relied on various sources of stem cells which can only presently produce very limited quantities.
By taking an alternative approach the scientists have generated the first human immortalized adult erythroid line (Bristol Erythroid Line Adult or BEL-A). In doing so, they have demonstrated a feasible way to sustainably manufacture red cells for clinical use from in vitro culture.
Globally, there is a need for an alternative red cell product. Cultured red blood cells have advantages over donor blood, such as reduced risk of infectious disease transmission.
Scientists have been working for years on how to manufacture red blood cells to offer an alternative to donated blood to treat patients.
The first therapeutic use of a cultured red cell product is likely to be for patients with rare blood groups because suitable conventional red blood cell donations can be difficult to source.
The patients who might benefit most are those with complex and life-limiting conditions like sickle cell disease and thalassemia. These require multiple transfusions of well-matched blood. The intention is not to replace blood donation but provide specialist treatment for specific patient groups.
The cells were cultured at the University of Bristol and at NHS Blood and Transplant's Filton site.
NHS Blood and Transplant needs to collect 1.5 million units of blood each year to meet the needs of patients across England and the ongoing need for life saving blood donations remains. It would be many years before manufactured cells could be available on a large scale.
The agency announced plans for clinical trials of manufactured blood in 2015. This first trial, due to start by the end of 2017, will not use Bel-A cells, but instead will use manufactured red cells from stem cells in a normal blood donation.
Citation: Kongtana Trakarnsanga et al., "An immortalized adult human erythroid line facilitates sustainable and scalable generation of functional red cells," Nature Communications, 2017; 8: 14750 DOI: 10.1038/ncomms14750
Contact: Jan Frayne, Jan.Frayne@bristol.ac.uk
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Advanced Stem Cell Technology|
|Publication:||Stem Cell Research News|
|Date:||Apr 10, 2017|
|Previous Article:||"Mini-brains" cultured in the petri dish.|
|Next Article:||Novel method for ambient storage of living cells and tissues.|